- Home
- CGBD vs AVTX Comparison
CGBD vs AVTX Comparison
Compare CGBD & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CGBD | AVTX |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 741.0M | 710.1M |
| IPO Year | 2013 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CGBD | AVTX |
|---|---|---|
| Price | $10.48 | $6.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | $12.21 | ★ $36.60 |
| AVG Volume (30 Days) | 466.4K | ★ 2.3M |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | ★ 16.08% | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.25 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $9.95 | $6.53 |
| 52 Week High | $13.28 | $24.27 |
Technical Indicators
Market Signals| Indicator | CGBD | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.80 | 16.78 |
| Support Level | $9.95 | N/A |
| Resistance Level | $10.78 | $20.54 |
| Average True Range (ATR) | 0.25 | 0.92 |
| MACD | 0.02 | -0.53 |
| Stochastic Oscillator | 62.34 | 1.71 |
Price Performance
Historical ComparisonAbout CGBD Carlyle Secured Lending Inc.
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.